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doi:10.1016/j.jtcvs.2003.12.0301682 The Journal of Thoracic and CardObjective: Tricuspid valve replacement in children is associated with a nonnegli-
gible complication rate because of specific disadvantages of mechanical or biologic
prostheses. The objective of this study was to examine the midterm clinical out-
comes of tricuspid valve replacement with a mitral homograft in 8 children with
unreparable rheumatic tricuspid valve involvement.
Methods: Between 1993 and 2003, tricuspid valve replacement with a mitral
homograft was performed in 8 patients (2 male and 6 female patients; mean age,
14.2 years) with rheumatic tricuspid valve disease. All patients were in New York
Heart Association class III or IV. In all patients with rheumatic valve disease,
conservative operations had previously been performed on the tricuspid valve
during concomitant left-sided surgical intervention. Mean follow-up was 56  12
months and was complete.
Results: There were no operative or late deaths. All patients were alive at the most
recent follow-up contact and were in New York Heart Association functional class
I or II. None of the patients required homograft-related reoperation. At the most
recent echocardiograhic examination, 6 patients had trivial residual tricuspid regur-
gitation, and 2 had mild tricuspid regurgitation. None of the patients had maximal
transvalvular tricuspid gradients greater than 2 mm Hg during their yearly follow-up
visits.
Conclusion: On the basis of our midterm results, tricuspid valve replacement with
a mitral homograft in children seems to be a valuable alternative surgical option.
Tricuspid valve (TV) dysfunction of rheumatic origin is usually as-sociated with the involvement of the left-sided valves and cangenerally be corrected by using different annuloplasty or repairtechniques if its severity requires intervention. However, in a fewcases, TV lesions are not amenable to repair, and thus replacementbecomes unavoidable. The choice of a valve substitute in the tricus-
pid position remains a mechanical or biologic prosthesis. Despite model changes
and refinements, mechanical prostheses are predisposed to a high rate of thrombosis
caused by lower pressures and slower flow rates in the right cardiac cavities. On the
other hand, bioprostheses are threatened by their structural deterioration over time.
In view of these problems, we considered it of interest to replace the severely
rheumatically involved TV with a mitral homograft. The purpose of this review is
to examine the technical, as well as the clinical, aspects of this experience obtained
in 8 patients and to report our midterm results.
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DPatients and Methods
In our institution, over a 10-year period between September 1993
and September 2003, 227 children with mitral rheumatic valve
disease, aortic rheumatic valve disease, or both underwent surgical
intervention for the first time. At the time of the initial operation,
115 of the children underwent mitral valve (MV) repair, and 30 of
them underwent MV replacement; a mechanical prosthesis was
used in 27 of these latter patients, and a bioprosthesis was used in
3 of them. All these patients were operated on by the first author.
Seventy-three of these 227 patients underwent mitral and aortic
valve repair (cusp extension), and 9 of them underwent MV repair
and concomitant aortic valve replacement with a cryopreserved
aortic homograft. Of the total of 227 patients, 49 required con-
comitant intervention on their TV during the initial left-sided
valvular surgery, indicating a prevalence of 21.6%. Hemodynam-
ically significant functional tricuspid insufficiency (TI) was
present in 37 (16.3%) patients. Before the initial operation, trans-
thoracic echocardiography (TTE) was performed to assess the
degree of functional TI, which was estimated as moderate to severe
(grade III) in 31 patients and severe (grade IV) in 6 patients.
Patients with grade III TI underwent concomitant De Vega annu-
loplasty, and those with severe functional TI (grade IV) underwent
a concomitant Carpentier-Edwards tricuspid ring annuloplasty. In
the second subset of 12 patients with organic TV lesions, 4 had
predominantly severe stenotic lesions (maximal gradient, 8 mm
Hg), and 8 of them had predominantly insufficient valves with
grade III or IV insufficiency. The 4 patients with predominant
tricuspid stenosis underwent concomitant commissurotomy asso-
ciated with De Vega annuloplasty, and the 8 patients with pre-
dominant TI underwent a concomitant Carpentier-Edwards ring
annuloplasty. In all these patients, the TI was reevaluated by
means of TEE after being temporarily weaned from cardiopulmo-
nary bypass (CPB) after the left-sided valvular intervention. There
was no discrepancy in terms of severity of TI between the preop-
erative TTE and peroperative transesophageal post-MV repair
echocardiographic assessment. Tricuspid annuloplasty was then
carried out on a beating heart during CPB.
From 1997 through 2003, 8 of these 12 children with organic
TV lesions in whom conservative operations had been performed
required a second intervention on their TV. The pathology encoun-
tered at the time of redo operation was predominantly severe
recurrent TV stenosis (maximal gradient,8 mm Hg) in 5 patients
and predominantly grade III or IV TI in the remaining 3 patients.
One of these 5 patients with tricuspid stenosis had initially under-
gone a ring annuloplasty because of predominantly organic TI.
However, at the time of the initial operation, the TV already
presented a mild component of commissural fusion that evolved
over time to become predominantly stenotic, probably induced by
new episodes of recurrent rheumatic attacks.
Organic involvement of the TV was evident in all 12 patients
on the preoperative TTE and subsequently confirmed visually
during surgical intervention in 8 of them. The presence of com-
missural fusion, leaflet thickening or retraction, or both was con-
sidered as qualifying for organic involvement (Figure 1).
Eight patients undergoing TV replacement with a mitral ho-
mograft constitute our population in this clinical review. All these
patients were again operated on by the first author. There were 6
female and 2 male patients, ranging in age from 12 to 16 years
The Journal of Thoracic(mean, 14.2 years). As mentioned before, all patients had previ-
ously undergone open valve surgery. Two of them had previous
aortic valve replacement with a cryopreserved aortic homograft
associated with MV repair and tricuspid commissurotomy with De
Vega annuloplasty. The remaining 6 patients had undergone pre-
vious MV repair. Concomitant tricuspid commissurotomy associ-
ated with De Vega annuloplasty had been performed in 2 of them,
and a concomitant Carpentier-Edwards ring annuloplasty had been
performed in 4 of them. In all 8 patients, the mean time period
between initial valve surgery and TV replacement was 96  13
months (range, 23-156 months). The tricuspid pathology encoun-
tered at the time of TV replacement was pure tricuspid stenosis in
5 patients and a combination of stenosis with predominant TI in
the other 3 patients. The mean of maximal tricuspid transvalvular
gradients measured by means of TTE in the 5 patients with pure
tricuspid stenosis was 12 mm Hg (range, 8-16 mm Hg). Five
patients were in New York Heart Association (NYHA) functional
class IV, and 3 patients were in NYHA class III. Ascites was
present in 2 patients, hepatomegaly in 4 patients, and peripheral
limb edema in 5 patients. No concomitant cardiac procedure was
necessary in these cases during the redo operations. TTE evalua-
tion of the other cardiac valves before redo operations showed
good functioning of the aortic homograft, with trivial diastolic leak
in 2 patients and residual mitral leaks in 8 patients (mild in 6
patients and moderate in 2 patients). The mean transvalvular mitral
gradient in these 8 patients was 4 2 mm Hg (range, 3-8 mm Hg).
All patients underwent median resternotomy after cannulation
of the femoral vein and artery. Adhesions were liberated, and the
superior vena cava was selectively cannulated with a curved ve-
nous cannula. TV replacement was performed in all cases on a
beating heart through a right atriotomy after snaring both venae
cavae. The TV was completely removed by incising the valve
circumferentially. Some of the septal leaflet was preserved to avoid
atrioventricular block by allowing for the suture of the homograft’s
posterior muscular rim to this remnant of the septal leaflet. The
chordae tendinae were removed from the tips of the papillary
Figure 1. TV stenosis caused by organic involvement of rheu-
matic origin.muscles. The size of the homograft had been previously deter-
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Dmined by means of measurements made on echocardiography,
with the most important dimension being the anteroposterior di-
ameter of the tricuspid orifice during diastole. A mitral homograft
was chosen so that the length of its anterior leaflet was approxi-
mately the same as the anteroposterior diameter of the tricuspid
orifice. On the basis of our experience, neither the length of the
MV chordae tendinae nor the configuration of the papillary mus-
cles is important in the choice of the appropriate mitral homograft
dimensions. In preparation for subsequent ring annuloplasty, hor-
izontal mattress sutures of 2-0 braided polyester were placed
around the perimeter of the tricuspid annulus, except for the
anteroseptal commissure area and half of the septal annulus close
to this commissure. After thawing, the cryopreserved homograft
was trimmed by cutting away the excess myocardium from the
annulus of the mitral homograft. The anterior papillary muscle was
shortened, leaving only 8 to 10 mm of tissue below its chordal
attachments. This shortening provides some ability to set the
chordal length and hence avoids a deeper incision into the inter-
ventricular septum. The posterior papillary muscle, on the other
hand, was kept intact to have enough tissue to place it through the
small ventriculotomy on the diaphragmatic surface of the right
ventricle parallel to the posterior descending branch of the coro-
nary artery (Figure 2, A). The most appropriate site for implanta-
tion of the posterior papillary muscle was chosen by measuring the
length of the posterior primary mitral chordae and applying the
same length to the distance from the tricuspid annulus to the
eventual site of implantation on the diaphragmatic surface of the
right ventricle. The length of the anterior chordae tendinae was
then measured, and the same length was applied to the distance
from the septal annulus to the anteroseptal commissure on the
interventricular septum to determine the eventual implantation site
of the anterior papillary muscle. An oblique incision was carefully
performed at this site by detaching a muscular layer of 2 cm in
depth from the interventricular septum. The anterior papillary
muscle was then inserted into this opening and secured with a
running 3-0 polypropylene suture passed through the detached
layer and the interventricular septum (Figure 2, B). The rationale
for the implantation into the interventricular septum rather than the
right ventricular anterior wall was to avoid any interference with
the right ventricular outflow tract flow. The mitral homograft was
attached to the tricuspid annulus with continuous stitches of 4-0
polypropylene after aligning the posterior leaflet between the an-
teroseptal commissure and the middle of the posterior tricuspid
annulus (Figure 2, C). The replaced TV was then supported with a
Carpentier-Edwards tricuspid ring (Figure 2, D). The size of this
ring was chosen according to the sizer corresponding to the surface
of the anterior leaflet of the mitral homograft. The size of the ring
was 32 mm in 6 patients and 34 mm in the other 2 patients. Valve
competence after repair was then tested by means of infusion of
saline under pressure into the right ventricle after temporarily
clamping the ascending aorta together with the pulmonary trunk.
No patients had either prophylactic anticoagulant or antiplatelet
regimens after surgical intervention.
Results
All patients survived the operation and are alive at the time
of this report. No mitral homograft–related complications
1684 The Journal of Thoracic and Cardiovascular Surgery ● Junwere encountered in these 8 patients. All patients were in
sinus rhythm postoperatively, except for 2 patients who had
atrial flutter–fibrillation that responded to amiodarone. Mi-
tral homograft function was assessed by means of 2-dimen-
sional echocardiography and Doppler color flow velocity
both preoperatively and postoperatively. Postoperative
mean length of hospital stay was 9  2 days (range, 7-12
days). The mean follow-up period was 56  8 months
(range, 5-80 months). All patients had regular TTE studies
before hospital discharge and at the first, third, and sixth
postoperative months. Four patients who were referred to
our institution from African countries by a welfare founda-
tion returned to their countries of origin 6 months after their
operations and were then followed by means of question-
naires sent to their referring cardiologists, who evaluate the
homograft function at regular yearly TTE studies. At the
sixth postoperative month, echocardiographic examination
showed that 2 of these 4 patients had trivial residual TI, and
2 of them had mild residual TI. The maximal transvalvular
gradients across the homograft were 2 mm Hg in 3 patients
and 1.4 mm Hg in 1 patient. Up to the most recent follow-up
study, referring cardiologists did not find any significant
changes in terms of these echocardiographic parameters.
The other 4 patients had regular yearly TTE examinations.
In all 4 patients, echocardiographic studies showed satisfac-
tory functioning of the mitral homograft over time (Figure
3). In these same 4 patients, the last echocardiographic
study showed that the residual leak was trivial, and the
maximal transvalvular gradient was estimated at 2 mm Hg
in 3 patients and at 1.2 mm Hg in 1 patient. Moreover, there
was no evidence of calcification or progressive leaflet re-
striction on repeated TTE studies over the follow-up period.
One of these children was referred to our institution 3 years
after the replacement of her TV with a mitral homograft
because of progression of the degree of residual mitral
insufficiency of her native valve from moderate to severe. In
this patient the MV had been replaced with a porcine
bioprosthesis. At the time of reintervention, the mitral ho-
mograft in the tricuspid position was explored through a
right atriotomy. The mobility of both leaflets was perfect,
the papillary muscles were completely incorporated into the
myocardium, and the prosthetic ring was entirely covered
by fibrosis. Saline injection into the right ventricle showed
good coaptation between both leaflets and no residual leak
(Figure 4). Observation of papillary muscle healing at the
time of reintervention for MV surgery showed secure ap-
proximation of the graft to the recipient. The donor papillary
muscles appeared to have been totally replaced by scar
tissue, leaving the homograft chordae tendineae attached to
the tips of the papillary muscles. At the last follow-up study,
6 patients were in NYHA class I, and 2 were in NYHA class
II.
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DDiscussion
Tricuspid annuloplasty is an excellent surgical technique
and yields satisfactory results in the correction of functional
TI. Although organic TV disease can be initially repaired in
95% of cases, subsequent TV replacement becomes man-
datory in some cases because of the progression of rheu-
matic valvular disease or the ignorance of its severity during
1
Figure 2. A, Implantation of the posterior papillary mu
the posterior descending branch of the coronary arter
trench created in the interventricular septum (arrow
annulus. D, Carpentier-Edwards prosthetic ring.the initial repair combined with left-sided valve surgery.
The Journal of ThoracicSince 1993, when Pomar and Mestres2 published their
16-month experience of total TV replacement with a mitral
homograft in 3 patients with right-sided infective endocar-
ditis and demonstrated the technical feasibility and reliabil-
ity of the operation, homograft replacement of the TV
became an appealing alternative to biologic or mechanical
prostheses. Many reports then described TV replacement
into the small right ventriculotomy (arrow) parallel to
Implantation of the anterior papillary muscle into the
Attachment of the mitral homograft to the tricuspidscle
y. B,
). C,with a mitral homograft with satisfactory midterm results
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Dand complete clinical cure of right-sided infective endocar-
ditis.3-5
When a decision is made to replace the TV, the choice
between mechanical and biologic prostheses remains con-
troversial. Both types of valvular substitutes have specific
advantages and disadvantages, especially in the pediatric
population, for which an ideal substitute has yet to be
developed. Some authors have reported that bioprostheses
in the tricuspid position perform well up to 10 years after
implantation but can show some structural deterioration,
this finding being especially pronounced in children.6-9
Kawahira and colleagues10 reported a stenosis rate of 57%
caused by calcification of the implanted bioprostheses in
children at between 4 and 9 years after initial replacement.
The lower pressures and flow rates in the right cardiac
cavities predispose mechanical prostheses to a high inci-
dence of valve thrombosis despite improvements in the new
10-12
Figure 3. Echocardiographic control at the 50th postoperative
month showing good coaptation surface between leaflets (arrow)
in systole (A) with no residual leak (B).bileaflet design. Although the outlook for these patients
1686 The Journal of Thoracic and Cardiovascular Surgery ● Junis excellent, the recommended level of anticoagulation for a
mechanical prosthesis (international normalized ratio of
3.5-4.5) in the tricuspid position carries the risk of hemor-
rhage. The risk and inconvenience of anticoagulation be-
comes even greater in children and young female patients
during childbearing years. Moreover, anticoagulant medica-
tion is undesirable in children who live in some developing
countries where no adequate facilities for periodic assess-
ments of international normalized ratio are available. For
these above-mentioned reasons, we consider TV replacement
with a mitral homograft a valuable alternative surgical option.
TV replacement with a mitral homograft is a technically
challenging operation, the most crucial point being the
positioning of the mitral homograft in the right ventricle.
Locating the proper points of implantation of the mitral
papillary muscles and attaching them should be properly
done, although on the right side, the conditions affecting the
security of fixation appear to be somewhat different, possi-
bly resulting from reduced stress on the chordae in a low-
pressure cavity. The length of the homograft’s anterior
leaflet is the key factor determining the choice of the correct
homograft size. This length should be longer than the an-
teroposterior diameter of the tricuspid annulus in diastole, as
measured on TTE, to ensure a satisfactory coaptation line
between both leaflets during systole, which is further rein-
forced by an annuloplasty ring. Each of these 3 steps of the
operation, which can be carried out on a beating heart
during CPB by bicaval cannulation, standardizes the proce-
dure in terms of the reproducibility and predictability of
midterm results. Thanks to the use of a systematic criterion
for the choice of valve size and the adjustment of chordal
length, the degree of immediate residual TI, which varied
from trivial to mild in our series, remained stable during the
Figure 4. Mitral homograft in the tricuspid position 62 months
after surgical intervention showing good coaptation between
both leaflets after saline injection into the right ventricle.follow-up period. This fact also proves that the residual
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Dregurgitation present just after implantation is directly re-
lated to the surgical procedure and not to the dysfunction of
the graft.
It is speculated that differences between the structural
change of implanted bioprostheses in the mitral and tricus-
pid positions might mainly be due to the effect of mechan-
ical stress on the cusps. We believe this hypothesis is also
valid for mitral homografts in the tricuspid position, as
demonstrated with an aortic homograft valve functioning
for 28 years in the tricuspid position.13 Despite this unique
case, further experience is needed to assess the long-term
performances of mitral homografts in the tricuspid position.
In summary, the mitral homograft in the tricuspid posi-
tion is a promising valvular substitute for the pediatric
population in whom anticoagulant medication is not other-
wise indicated or is undesirable. Long-term follow-up is
obviously needed to ascertain clinical results and to com-
pare hemodynamic performance with that of biologic pros-
theses.
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